

# Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010–2017

Kimiko Ubukata, Misako Takata, Miyuki Morozumi, Naoko Chiba, Takeaki Wajima, Shigeo Hanada, Michi Shouji, Megumi Sakuma, Satoshi Iwata; the Invasive Pneumococcal Diseases Surveillance Study Group

To clarify year-to-year changes in capsular serotypes, resistance genotypes, and multilocus sequence types of *Streptococcus pneumoniae*, we compared isolates collected from patients with invasive pneumococcal disease before and after introductions of 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively). From April 2010 through March 2017, we collected 2,856 isolates from children and adults throughout Japan. Proportions of PCV13 serotypes among children decreased from 89.0% in fiscal year 2010 to 12.1% in fiscal year 2016 and among adults from 74.1% to 36.2%. Although nonvaccine serotypes increased after introduction of PCV13, genotypic penicillin resistance decreased from 54.3% in 2010 to 11.2% in 2016 among children and from 32.4% to 15.5% among adults. However, genotypic penicillin resistance emerged in 9 nonvaccine serotypes, but not 15A and 35B. Multilocus sequence typing suggested that resistant strains among nonvaccine serotypes may have evolved from clonal complexes 156 and 81. A more broadly effective vaccine is needed.

Among persons in all age groups, but particularly infants and elderly persons, *Streptococcus pneumoniae* remains a major cause of invasive pneumococcal disease (IPD) (e.g., pneumonia, meningitis, and sepsis), although generally effective antimicrobial agents are available (1). In the United States, 7-valent pneumococcal conjugate vaccine (PCV7) has been administered to children since 2000, resulting in both individual and herd immunity, with declines in pneumococcal infection among children and elderly persons (2–6). Unfortunately, introduction of PCV7

was followed by an increase in serotype 19A showing penicillin resistance and often multidrug resistance (5–8). In 2010, vaccination for children was upgraded to 13-valent pneumococcal conjugate vaccine (PCV13), which covers 6 additional serotypes: 1, 3, 5, 6A, 7F, and 19A (9). Introduction of PCV13 contributed to decreases in IPD (10,11), pneumonia (including community-acquired pneumonia without bacteremia) (12,13), and acute otitis media (14–16) caused by *S. pneumoniae* belonging to vaccine serotypes, especially 6A and 19A. As an indirect effect of wide administration of PCVs to children, pneumococcal infections in adults have also decreased, representing herd immunity (11,12,17–23).

Despite these benefits, in countries where PCV7 or PCV13 was introduced, proportions of disease preventable by PCVs gradually decreased because vaccine-serotype pneumococci were replaced by nonvaccine serotypes (NVTs). Increases in NVTs such as 6C, 15A/B/C, 23A, and 35B have been reported in the United States (24–28); 15A and 23B in Norway (18) and Germany (29); and 12F, 15A, 24F, and 35B in France (30).

In November 2010 in Japan, PCV7 vaccination use among children <5 years of age was introduced voluntarily by the Provisional Special Fund for the Urgent Promotion of Vaccination. In April 2013, PCV7 was officially incorporated into the vaccination program as public administration; in November of that year, PCV7 was replaced by PCV13. Promotion of PCV7 vaccination for children rapidly halved the number of IPD cases caused by vaccine-serotype pneumococci among children (31) and also produced a herd effect benefiting elderly persons (32). After PCV7 introduction, however, among persons of all ages, IPD caused by non-PCV7 serotypes such as 19A, 15A, 15B, 15C, 22F, and 24F showed relative increases in 2013. In November 2014, the Japanese Ministry of Health, Labour and Welfare began promoting vaccination of adults ≥65 years of age with 23-valent pneumococcal polysaccharide vaccine

Author affiliations: Keio University School of Medicine, Tokyo, Japan (K. Ubukata, M. Takata, M. Morozumi, N. Chiba, M. Sakuma, S. Iwata); Tokyo University of Pharmacy and Life Sciences, Tokyo (T. Wajima); Toranomon Hospital, Tokyo (S. Hanada); National Cancer Center Hospital, Tokyo (M. Shouji, S. Iwata)

DOI: <https://doi.org/10.3201/eid2411.180326>

(PPSV23). In this study, we aimed to clarify year-to-year changes in capsular serotypes, genotypes of penicillin and macrolide resistance, and diversity of sequence types (STs) in all pneumococcal isolates collected throughout Japan during April 2010–March 2017.

## Methods

### Patients and Pneumococcal Strains

We included all specimens from patients of any age with IPD. Pneumococcal isolates from normally sterile clinical samples were collected from clinical laboratories at 341 hospitals participating in this IPD surveillance study. Each hospital had a microbiology laboratory as described previously (31), and participating hospitals were distributed nearly uniformly throughout Japan. These hospitals took part in the surveillance project after written permission was granted by the laboratory director or hospital director. This study was approved by the Keio University School of Medicine Ethics Committee (approval no. 20140432).

A total of 2,856 pneumococcal strains were collected from April 2010 through March 2017 (online Technical Appendix Figure 1, <https://wwwnc.cdc.gov/EID/article/24/11/18-0326-Techapp1.pdf>). The first surveillance interval, April 2010–March 2011 (designated 2010), represented the pre-PCV7 period. The second surveillance interval, April 2011–March 2014 (designated 2011–2013, the PCV7 period), showed effects of PCV7 vaccination for children <5 years of age. The third surveillance interval, April 2014–March 2017 (designated 2014–2016, the PCV13 period), reflected PCV13 vaccination for children <5 years of age.

During the pre-PCV7 period, the rate of voluntary PCV7 vaccination among children in Japan was <10%. The PCV7 period corresponded to the Urgent Promotion of PCV7, a vaccination incentive program for children. The PCV7 vaccination rate throughout Japan was estimated at 50%–60% in 2011, 80%–90% in 2012, and >95% in 2013. During the PCV13 period, corresponding to substitution of PCV13 for routine vaccination, coverage remained >95%. In elderly persons ( $\geq 65$  years of age), the rate of vaccination with PPSV23, starting in 2014, has remained at  $\approx 54\%$  as of 2017 (Vaccine Medical Affairs of Merck Sharp and Dohme K.K., Tokyo, Japan, pers. comm., 2017 Apr 1).

Pneumococcal isolates were sent promptly from each clinical laboratory to the Department of Infectious Diseases, Keio University School of Medicine (Tokyo, Japan), accompanied by a survey form completed by the attending physician. In compliance with ethics guidelines for epidemiology in Japan, patients were not identified.

### Serotype and Resistance Genotype

We determined serotypes by using the capsular quellung test with antiserum purchased from Statens Serum

Institute (Copenhagen, Denmark). Alterations in 3 penicillin-binding protein genes that mediate  $\beta$ -lactam resistance in *S. pneumoniae* (*pbp1a*, *pbp2x*, and *pbp2b*) were identified by real-time PCR as described previously (33). The *mef(A)* and *erm(B)* genes, which mediate macrolide resistance, were also identified by real-time PCR (33). Quinolone resistance was analyzed by sequencing the quinolone resistance-determining region in the genes *gyrA*, *gyrB*, *parC*, and *parE* in strains showing MICs of levofloxacin exceeding 4  $\mu\text{g/mL}$ .

Genotypes (g) based on gene analysis were represented as follows: penicillin-susceptible *S. pneumoniae* (gPSSP), possessing 3 normal *pbp* genes; penicillin-intermediate *S. pneumoniae* (gPISP), subclassified as gPISP (*pbp2x*), gPISP (*pbp2b*), gPISP (*pbp1a+pbp2x*), gPISP (*pbp1a+pbp2b*), or gPISP (*pbp2x+pbp2b*); and penicillin-resistant *S. pneumoniae* (gPRSP), which possessed 3 abnormal *pbp* genes (31,33). Serotype and resistance genotype results were promptly reported to laboratory staff at each referring hospital.

### Susceptibility Testing

For all isolates, we redetermined the MICs of 6 antimicrobial agents by using agar-dilution methods with reference strains R6 and ATCC49619 (34). The agents tested were penicillin, ampicillin, cefotaxime, meropenem, vancomycin, and levofloxacin.

### Multilocus Sequence Typing

We performed multilocus sequence typing (MLST) analysis for all 2,849 isolates that could be cultured. Primers used for MLST were based on sequences listed at <https://pubmlst.org/spneumoniae/>. Clusters of related STs were analyzed by using eBURST version 3 (<http://eburst.mlst.net/>).

### Statistical Analyses

For statistical analyses, we used Ekuseru-Toukei 2015 software (Social Survey Research Information, Tokyo, Japan) and R software 3.5.0 (R Foundation of Computational Statistics, Vienna, Austria). We used the  $\chi^2$  and Fisher exact tests as appropriate. We considered  $p < 0.05$  to indicate statistical significance.

## Results

### Relationships between IPD Type and Patient Age

Relationships between IPD type and patient age are shown in Table 1. IPD types were classified into 4 categories: pneumonia with bacteremia (41.9%), including empyema and pleuritis; bacteremia with unknown focus (37.0%); meningitis (15.4%); and others (5.6%), including endocarditis, necrotizing fasciitis, cellulitis, arthritis, and spondylitis. Pneumonia with bacteremia was most common among adults, especially

**Table 1.** Invasive pneumococcal disease in all patients, by age group, Japan, April 2010–March 2017

Disease	Total, no. (%), n = 2,856	Age, y, no. (%)								p value
		≤2, n = 731	3–5, n = 181	6–17, n = 94	18–49, n = 201	50–64, n = 387	65–74, n = 530	75–84, n = 457	≥85, n = 275	
Pneumonia with bacteremia*	1,198 (41.9)	130 (17.8)	35 (19.3)	22 (23.4)	83 (41.3)	167 (43.2)	261 (49.2)	300 (65.6)	200 (72.7)	<0.001
Bacteremia with focus unknown	1,058 (37.0)	455 (62.2)	116 (64.1)	33 (35.1)	46 (22.9)	104 (26.9)	158 (29.8)	92 (20.1)	54 (19.6)	<0.001
Meningitis	440 (15.4)	109 (14.9)	22 (12.2)	34 (36.2)	56 (27.9)	80 (20.7)	79 (14.9)	43 (9.4)	17 (6.2)	<0.001
Other†	160 (5.6)	37 (5.1)	8 (4.4)	5 (5.3)	16 (8.0)	36 (9.3)	32 (6.0)	22 (4.8)	4 (1.5)	0.002

\*Includes empyema (n = 32) and pleuritis (n = 25).

†Includes endocarditis (n = 6), necrotizing fasciitis (n = 1), arthritis (n = 34), cellulitis (n = 20), and spondylitis (n = 7).

those ≥75 years of age; however, among children <5 years of age, bacteremia with unknown focus was most common ( $p < 0.001$  for each). Meningitis and other IPDs were represented in higher proportions among persons 6–64 years of age ( $p < 0.001$ ) than among those in other age groups ( $p = 0.002$ ).

### Changes in Serotypes

Figure 1 shows yearly changes in pneumococcal capsular serotypes among children and adults. Pneumococcal capsular serotypes were classified into 4 groups: PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) (PCV7); PCV13 serotypes not included in PCV7 (1, 3, 5, 6A, 7F, and 19A) (PCV13–nonPCV7); PPSV23 serotypes not included in PCV13 (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F) (PPSV23–nonPCV13); and NVTs not including serotypes in PPSV23 and not including 6A. Among children, the proportion of PCV7 serotypes that accounted for 73.3% of serotype strains isolated from IPD patients during the pre-PCV7 period decreased rapidly to 7.4% in 2013 after PCV7 introduction (Figure 1). In contrast, in 2013, PCV13–nonPCV7 serotypes increased from 15.7% to 25.9%, PPSV23–nonPCV13 serotypes increased from 3.0% to 18.5%, and NVT serotypes increased from 8.0% to 48.1%. During 2014, after PCV7 was replaced with PCV13, the proportion of PCV13–nonPCV7 serotypes decreased by approximately half to 11.1% in 2016, while

PPSV23–nonPCV13 serotypes increased to 40.4%, in contrast to the PCV7 period.


Among adults, the proportions of PCV7 serotypes, which accounted for 43.6% of isolates during the pre-PCV7 period, decreased to 11.7% in 2013, when children were vaccinated with PCV7. However, proportions of the PPSV23–nonPCV13 doubled from 12.4% to 25.4% and NVTs doubled from 13.5% to 28.9%. PCV13–nonPCV7 serotypes decreased slightly after replacement by PCV13 in 2014, but PPSV23–nonPCV13 serotypes continued to increase.

### Serotype Changes during the Pre-PCV7, PCV7, and PCV13 Periods

Changes in serotypes of pneumococcal isolates collected between the pre-PCV7, PCV7, and PCV13 periods are shown in Table 2 for children and in Table 3 for adults. Among children, proportions of PCV7 serotypes decreased rapidly from 73.3% to 30.3% during the PCV7 period and decreased further to 2.3% during the PCV13 period ( $p < 0.001$ ). Among PCV13–nonPCV7 serotypes, serotype 19A apparently increased during the PCV7 period, but later it decreased significantly during the PCV13 period. PCV13–nonPCV7 serotypes decreased from 21.8% during the PCV7 period to 14.9% during the PCV13 period ( $p = 0.031$ ). Although serotypes 1 and 7F showed relative increases during the PCV13 period, most were isolated from patients ≥3 years of

**Figure 1.** Yearly changes in pneumococcal serotypes of isolates from A) 1,006 children and B) 1,850 adults with invasive pneumococcal disease in Japan, April 2010–March 2017. Specific percentages are indicated at points along data lines. Fiscal years extend from April 1 through March 31 of the following year. PCV13–nonPCV7 covers 6 serotypes (1, 3, 5, 6A, 7F, and 19A). PPSV23–nonPCV13 covers 11 serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F), but 2, 9N, and 17F were not isolated in this study. NVTs

represent other serotypes not included in PPSV23 and 6A. NVT, nonvaccine serotype; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.



**Table 2.** Distribution of pneumococcal serotypes among children before PCV7 and after introduction of PCV7 and PCV13, Japan, April 2010–March 2017\*

Serotype	No. (%)			p value†
	Pre-PCV7 period, 2010, n = 300	PCV7 period 2011–2013, n = 357	PCV13 period, 2014–2016, n = 349	
<b>PCV7</b>				
4	7 (2.3)	6 (1.7)	0	0.007
6B	83 (27.7)	49 (13.7)	2 (0.6)	<0.001
9V	9 (3.0)	2 (0.6)	1 (0.3)	0.005
14	34 (11.3)	9 (2.5)	0	<0.001
18C	4 (1.3)	4 (1.1)	1 (0.3)	0.336
19F	40 (13.3)	13 (3.6)	2 (0.6)	<0.001
23F	43 (14.3)	25 (7.0)	2 (0.6)	<0.001
Subtotal	220 (73.3)	108 (30.3)	8 (2.3)	<0.001
<b>PCV13–nonPCV7‡</b>				
1	0	5 (1.4)	13 (3.7)	<b>&lt;0.001</b>
3	4 (1.3)	7 (2.0)	4 (1.1)	0.724
5	0	0	0	NA
6A	15 (5.0)	6 (1.7)	2 (0.6)	0.001
7F	1 (0.3)	2 (0.6)	6 (1.7)	0.153
19A	27 (9.0)	58 (16.2)	27 (7.7)	0.001
Subtotal	47 (15.7)	78 (21.8)	52 (14.9)	0.031
<b>PPSV23–nonPCV13§</b>				
8	0	0	0	NA
10A	2 (0.7)	5 (1.4)	18 (5.2)	<b>&lt;0.001</b>
11A	2 (0.7)	1 (0.3)	4 (1.1)	0.356
12F	1 (0.3)	1 (0.3)	33 (9.5)	<b>&lt;0.001</b>
15B	0	15 (4.2)	26 (7.4)	<b>&lt;0.001</b>
20	0	1 (0.3)	0	NA
22F	3 (1.0)	16 (4.5)	19 (5.4)	<b>0.003</b>
33F	1 (0.3)	7 (2.0)	17 (4.9)	<b>0.001</b>
Subtotal	9 (3.0)	46 (12.9)	117 (33.5)	<b>&lt;0.001</b>
<b>NVT</b>				
6C	9 (3.0)	20 (5.6)	11 (3.2)	0.159
15A	2 (0.7)	25 (7.0)	36 (10.3)	<b>&lt;0.001</b>
15C	1 (0.3)	17 (4.8)	16 (4.6)	<b>&lt;0.001</b>
23A	4 (1.3)	13 (3.6)	10 (2.9)	0.176
24F	1 (0.3)	20 (5.6)	52 (14.9)	<b>&lt;0.001</b>
24B	2 (0.7)	4 (1.1)	12 (3.4)	0.197
34	1 (0.3)	6 (1.7)	7 (2.0)	0.126
35B	1 (0.3)	10 (2.8)	11 (3.2)	<b>0.016</b>
38	1 (0.3)	8 (2.2)	7 (2.0)	0.072
Other¶	2 (0.7)	2 (0.6)	9 (2.6)	<b>0.041</b>
Subtotal	24 (8.0)	125 (35.0)	171 (49.0)#	<b>&lt;0.001</b>

\*Years run from April 1 through March 31 of the following year. NA, not applicable; NVT, nonvaccine serotype; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

†p values compare the 3 surveillance periods; boldface indicates significant increase.

‡Serotypes added to PCV7.

§Serotypes contained in PPSV23 but not PCV13.

¶Includes 7C (n = 2), 16F (n = 2), 21 (n = 2), 23B (n = 3), 28A (n = 1), 37 (n = 1), and 31 (n = 2).

#One strain identified as nontypeable was excluded from the table.

age who had received PCV7 or a single dose of PCV13. To the contrary, proportions of PPSV23–nonPCV13 serotypes and NVTs increased significantly between the pre-PCV7 period and the PCV7 period, continuing to increase up to the PCV13 period ( $p < 0.001$  for each). In particular, 9 serotypes (10A, 12F, 15A, 15B, 15C, 22F, 24F, 33F, and 35B) increased significantly after introduction of PCV7 and PCV13.

Among adults, proportions of PCV7 serotypes decreased sharply, from 43.6% during the pre-PCV7 period to 24.2% during the PCV7 period and 7.3% during the PCV13 period, particularly for serotypes 4, 6B, 9V, 14, 19F, and 23F. PCV13–nonPCV7 serotypes increased in serotypes 7F and 19A, whereas 6A showed a significant

decrease because of cross-immunity with 6B (Table 3). PPSV23–nonPCV13 serotypes and NVTs increased respectively from 12.4% and 13.5% during the pre-PCV7 period to 21.9% and 24.9% during the PCV7 period and further to 27.8% and 30.9% during the PCV13 period ( $p < 0.001$  for each). In particular, significant increases were noted for serotypes 12F, 15C, 22F, 23A, 24F, and 35B. Tendencies to increase did not attain significance for serotypes 11A and 15A.

#### Changes in Penicillin and Other Resistance Genotypes

Figure 2 shows yearly changes of penicillin resistance genotypes among children and adults. Changes are shown from

**Table 3.** Distribution of pneumococcal serotypes in adults before PCV7 and after introduction of PCV7 and PCV13 administration to children, Japan, April 2010–March 2017\*

Serotype	No. (%)			p value†
	Pre-PCV7 period, 2010, n = 275	PCV7 period, 2011–2013, n = 695	PCV13 period, 2014–2016, n = 880	
<b>PCV7</b>				
4	14 (5.1)	27 (3.9)	4 (0.5)	<0.001
6B	42 (15.3)	39 (5.6)	22 (2.5)	<0.001
9V	7 (2.5)	7 (1.0)	6 (0.7)	0.042
14	21 (7.6)	41 (5.9)	6 (0.7)	<0.001
18C	1 (0.4)	3 (0.4)	2 (0.2)	0.642
19F	14 (5.1)	23 (3.3)	15 (1.7)	0.007
23F	21 (7.6)	28 (4.0)	9 (1.0)	<0.001
Subtotal	120 (43.6)	168 (24.2)	64 (7.3)	<0.001
<b>PCV13–nonPCV7‡</b>				
1	1 (0.4)	4 (0.6)	13 (1.5)	0.145
3	45 (16.4)	110 (15.8)	145 (16.5)	0.939
5	0	1 (0.1)	0	NA
6A	11 (4.0)	16 (2.3)	9 (1.0)	0.006
7F	9 (3.3)	9 (1.3)	33 (3.8)	<b>0.006</b>
19A	18 (6.5)	61 (8.8)	99 (11.3)	<b>0.045</b>
Subtotal	84 (30.5)	201 (28.9)	299 (34.0)	0.093
<b>PPSV23–nonPCV13§</b>				
8	0	2 (0.3)	0	NA
10A	10 (3.6)	34 (4.9)	54 (6.1)	0.244
11A	3 (1.1)	23 (3.3)	34 (3.9)	0.058
12F	5 (1.8)	5 (0.7)	63 (7.2)	<b>&lt;0.001</b>
15B	3 (1.1)	14 (2.0)	10 (1.1)	0.356
20	1 (0.4)	7 (1.0)	14 (1.6)	0.261
22F	10 (3.6)	63 (9.1)	59 (6.7)	<b>0.008</b>
33F	2 (0.7)	4 (0.6)	11 (1.3)	0.352
Subtotal	34 (12.4)	152 (21.9)	245 (27.8)	<b>&lt;0.001</b>
<b>NVT</b>				
6C	13 (4.7)	49 (7.1)	52 (5.9)	0.400
15A	6 (2.2)	28 (4.0)	47 (5.3)	0.068
15C	0	12 (1.7)	7 (0.8)	<b>0.034</b>
23A	2 (0.7)	33 (4.7)	50 (5.7)	<b>&lt;0.001</b>
24F	0	11 (1.6)	16 (1.8)	<b>0.049</b>
34	1 (0.4)	5 (0.7)	12 (1.4)	0.301
35B	7 (2.5)	22 (3.2)	55 (6.3)	<b>0.004</b>
38	3 (1.1)	7 (1.0)	11 (1.3)	0.955
Other¶	5 (1.8)	6 (0.9)	22 (2.5)	<b>0.042</b>
Subtotal	37 (13.5)	173 (24.9)#	272 (30.9)	<b>&lt;0.001</b>

\*Years run April 1– March 31 of the following year. NA, not applicable; NVT, nonvaccine serotype; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

†p values compare the 3 surveillance periods; boldface indicates significant increase.

‡Serotypes added to PCV7.

§Serotypes contained in PPSV23 but not PCV13.

¶Includes 6D (n = 2), 7C (n = 8), 13 (n = 1), 16F (n = 6), 18B (n = 5), 31 (n = 3), and 37 (n = 7).

#One strain identified as nontypeable was excluded from the table.

the pre-PCV7 period to the PCV7 period and further to the PCV13 period.

Among children, the proportion of gPRSP declined sharply from 54.3% in 2010 during the pre-PCV7 period to 20.4% in 2013 during the PCV7 period; gPSSP and gPISP (*pbp2x*) increased (Figure 2). In 2016 during the PCV13 period, proportions of gPRSP and gPISP (*pbp1a+2x*) further declined to 11.2% and 6.1%, respectively. However, gPISP (*pbp2b*) rapidly increased.


Among isolates from adults during the pre-PCV7 period, gPISP (*pbp2x*) was most common (34.9%), followed by gPRSP (32.4%) (Figure 2). gPSSP accounted for only 15.3%. Similar to the trend for children during the PCV7 and PCV13 periods, gPRSP among adults continually

decreased to 15.5% in 2016. However, also in 2016, gPISP (*pbp2b*) among adults increased to 8.3%, similar to the trend among children.

During the surveillance periods, macrolide-resistant isolates possessing *mef(A)* or *erm(B)* genes remained consistently high. Among children, proportions were 93.8% in 2010 and 91.8% in 2016; among adults, proportions were 87.2% in 2010 and 89.8% in 2016. Prevalence of resistance genes was 59.8% for the *erm(B)* gene mediating high macrolide resistance, 19.6% for the *mef(A)* gene mediating intermediate resistance, and 11.6% for both *erm(B)* and *mef(A)* genes (data not shown).

Isolates with mutations in both *gyrA* and *parC* genes, which are involved in resistance to quinolones, especially

**Figure 2.** Yearly changes in genotypic penicillin resistance in isolates from A) 1,006 children and B) 1,850 adults with invasive pneumococcal disease in Japan, April 2010–March 2017. Fiscal years extend from April 1 through March 31 of the following year. Genotypes based on abnormal *pbp1a*, *pbp2x*, and *pbp2b* genes were identified by real-time PCR and are represented as gPRSP (1a+2x+2b), gPISP (1a+2x), gPISP (1a+2b), gPISP (2x+2b), gPISP (2x), gPISP (2b), and gPSSP. g, genotype; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PISP, penicillin-intermediate *Streptococcus pneumoniae*; PRSP, penicillin-resistant *S. pneumoniae*; PSSP, penicillin-susceptible *S. pneumoniae*.



levofloxacin, accounted for <1% of all isolates. These isolates showed no tendency to increase.

### Relationships between Serotypes and Resistance Genotypes

Changes of serotypes and the penicillin resistance genotypes during the 3 periods (pre-PCV7, PCV7, and PCV13) are shown in online Technical Appendix Figures 2 (for children) and 3 (for adults). Decreases in gPRSP (*pbp1a+2x+2b*) and gPISP (*pbp1a+2x*) were closely related to reduction of serotypes 6B, 14, 19F, 23F, and 6A in children and adults during the PCV7 period, and this link became stronger during the PCV13 period. Serotype 19A, including several gPRSP, decreased by half among children during the PCV13 period, but this change has not yet become evident among adults.

The proportions of PPSV23–nonPCV13 and NVT serotypes generally increased among children and adults during the PCV13 period. gPRSPs were newly identified in serotypes 15B (n = 1), 15C (n = 1), and 16F (n = 2) in isolates from children and in serotypes 6C (n = 2), 6D (n = 2), 13 (n = 1), 15B (n = 1), 15C (n = 1), 16F (n = 2), 23A (n = 1), 23B (n = 1), and 34 (n = 1) in isolates from adults.

Relationships between genotypic macrolide and penicillin resistances and serotypes are shown in online Technical Appendix Table 1. Strains possessing *mef(A)*, *erm(B)*, or both were identified in most of the serotypes, with the exception of serotypes 8, 18B, 28A, and 31. No relationship was observed between macrolide resistance and penicillin resistance.

### Antimicrobial Susceptibility by Genotype

Susceptibilities (50% MIC, 90% MIC, and MIC range) of 6 parenteral agents (penicillin, ampicillin, cefotaxime, meropenem, vancomycin, and levofloxacin) for


*S. pneumoniae* strains obtained from April 2014 through March 2017, corresponding to the PCV13 period (n = 1,229), are shown in online Technical Appendix Table 2. Relationships between 6 genotypes for penicillin resistance and MICs of penicillin, ampicillin, cefotaxime, and meropenem for the strains are shown in online Technical Appendix Figure 4.

Because prevalence of gPRSP was reduced by the PCV vaccinations, the distribution of susceptibilities was shifted in favor of greater susceptibility, especially after introduction of PCV7. For penicillin and ampicillin, 90% MICs were 2 µg/mL; for cefotaxime, 1 µg/mL; and for meropenem, 0.5 µg/mL. gPRSP isolates showing high resistance for penicillin (≥8 µg/mL) were not found.

### STs by Serotypes and Resistance Genotypes

STs by eBURST analyses for 2,849 pneumococcal strains are shown in Figure 3. These data are distinguished by ST and vaccine serotype (PCV7, PCV13–nonPCV7, PPSV23–nonPCV13, and NVT). Details of relationships among clonal complexes (CCs), STs, serotypes, and resistance genotypes are listed in online Technical Appendix Table 3.

By MLST analysis, 273 different STs were identified. STs of gPRSP in 11 serotypes included in PPSV23–nonPCV13 and NVTs were noteworthy: 15B (n = 2), ST242 (belonging to CC242) and ST83 (derived from CC81); 6C (n = 2), ST8352 (CC156) and ST5832 (CC5832); 6D (n = 2), ST90 (CC156) and ST282 (CC81); 13 (n = 1), ST10303 (CC156); 15A (n = 77), ST63, ST2105, ST2771, ST8354, and ST12000 (all CC63); 15C (n = 2), ST83 and ST6138 (CC81); 16F (n = 4), ST8351 (CC3117); 23A (n = 1), ST9619 (CC156); 23B (n = 1), ST2372 (CC156); 34 (n = 1), ST9395 (CC15); 35B (n = 55), ST558, ST1204, and



**Figure 3.** An eBURST (<http://eburst.mlst.net/>) diagram displaying pneumococcal sequence types (STs) causing invasive pneumococcal disease across patients of all age groups in Japan. All 2,849 strains are distinguished by colors to indicate PCV7, PCV13–nonPCV7, PPSV23–nonPCV13, and NVT. Size of each circle reflects the number of strains. ST numbers shown in red represent genotypes for penicillin-resistant *Streptococcus pneumoniae* confirmed among PPSV23–nonPCV13 and NVT as follows: 15B (n = 2), ST242 and ST83; 6C (n = 2), ST8352 and ST5832; 6D (n = 2), ST90 and ST282; 13 (n = 1), ST10303; 15A (n = 77), ST63 (n = 73), ST2105, ST2771, ST8354, and ST12000; 15C (n = 2), ST83 and ST6138; 16F (n = 4), ST8351; 23A (n = 1), ST9619; 23B (n = 1), ST2372; 34 (n = 1), ST9395; 35B (n = 55), ST558 (n = 49), ST1204, ST7809, ST7990, and ST156. NVT, nonvaccine serotype; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine.

ST7809 (all CC558); and the remaining ST156 (CC156) and ST7990 (singleton).

A total of 6 STs identified as gPRSP belonged to the large CC156 (Figure 4). STs of 3 serotypes (13, 23A, and 23B) were derived from ST338, which includes the Colombia<sup>23F-26</sup> clone from the Pneumococcal Molecular Epidemiology Network (PMEN). Serotype 6C was derived from ST172, a neighbor of ST338. Of strains with serotypes 6D and 35B, each strain was distant from other gPRSPs. STs of serotypes 15B, 15C, and 6D among gPRSP belonged to CC81 (online Technical Appendix Figure 5).

In addition, STs of certain serotypes increasing in PPSV23–nonPCV13 and NVTs were noted. Serotype 12F was ST4846 (CC1527), 22F was ST433 (CC433), 23A included ST338 and ST5242 (CC156), and 24B/24F included ST2572 and ST5496 (CC2572).

## Discussion

Wide use of PCVs among children in many countries has contributed to a dramatic reduction in incidence of IPD (6,10,11,35–38), pneumonia (12,13,39), and acute otitis media (14,15) caused by *S. pneumoniae*, while providing indirect herd immunity benefits for adults (11,23,40,41). Replacing PCV7 with PCV13 decidedly decreased

serotype 19A isolates among causative pathogens, but in several countries, NVTs such as 15A and 35B increased. Gradual increases of NVTs, unfortunately, have blunted the effectiveness of conjugate vaccines (42).

In Japan, introduction of PCV7 in children <5 years of age began as an official government program in November 2010, continuing until it was replaced with PCV13 in November 2013. PPSV23 vaccination for adults ≥65 years of age was implemented in October 2014. We organized nationwide surveillance beginning in April 2010, with collection of pneumococcal strains from IPD patients in all age groups throughout Japan. In this article, we describe details of changes of serotypes, penicillin resistance genotypes, and MLST analyses that have followed implementation of PCV7 and PCV13 vaccination. As in other countries where PCV13 has been introduced, proportions of PCV13 serotypes among isolates from children and adults decreased significantly during the PCV13 period. In Japan, where population density is high, the decrease suggests early effectiveness of herd immunity not only among children but also among adults. However, serotypes 7F and 19A, included in PCV13, seem to be increasing among adults; for these serotypes, no indirect effect for adults is evident. These findings indicate a need for PCV13 vaccination of elderly





derived from ST172 and ST338, which diverged from ST171 (Figure 4, letter d) and evolved further. Serotypes of many isolates registered as ST172 or ST338 were either NVTs or one of the serotypes of PCV13–nonPCV7. These findings suggested that wide use of PCVs led to a decrease in STs belonging to PCV7 and PCV13 serotypes, but some STs detected among NVTs escaped from the vaccine pressure and are increasing, such as ST338. However, whether the new gPRSPs emerged in Japan or originated in another country is unknown.

Capsular switching in *S. pneumoniae* can occur as a result of homologous recombination at a site outside the *cps* locus. Of note, *pbp1a* genes are located upstream and *pbp2x* genes are located downstream of the *cps* locus (46–48). Recombination including these 2 *pbp* genes, driven by antimicrobial pressure, can result in concomitant exchange of the *cps* locus. Such new ST strains arising from capsular switching can exhibit penicillin resistance and increase under antimicrobial selection pressure. The diversity of serotypes, resistant genotypes, and STs we describe reflects adaptability of *S. pneumoniae* to the human environment.

In conclusion, to assess whether gPRSP in NVTs will increase in the near future, sustained surveillance for IPD is needed. Control of pneumococcal infections, particularly in elderly and immunocompromised persons, requires development of further multivalent conjugate vaccines, new vaccines targeting a different microbial component, or both. Global consensus for appropriate use of antimicrobial drugs is also valuable for limiting spread of new resistant strains within and beyond national borders.

### Acknowledgments

We thank Madoka Naitoh and Shinji Masuyoshi for their assistance. We are also grateful to the laboratory personnel and physicians who participated in this study.

Our study was funded in part by a grant to K.U. under the category “Research on Emerging and Re-emerging Infectious Diseases” (H22-013) from the Japanese Ministry of Health, Labour and Welfare.

### About the Author

Dr. Ubukata is a microbiologist at Keio University School of Medicine. Her research interests include molecular epidemiology, particularly with respect to respiratory infection, as well as comprehensive rapid identification of pathogens.

### References

- O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al.; Hib and Pneumococcal Global Burden of Disease Study Team. Burden of disease caused by *Streptococcus pneumoniae* in children younger than 5 years: global estimates. *Lancet*. 2009;374:893–902. [http://dx.doi.org/10.1016/S0140-6736\(09\)61204-6](http://dx.doi.org/10.1016/S0140-6736(09)61204-6)
- Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med*. 2003;348:1737–46. <http://dx.doi.org/10.1056/NEJMoa022823>
- Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease—United States, 1998–2003. *MMWR Morb Mortal Wkly Rep*. 2005;54:893–7.
- Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al.; Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. *JAMA*. 2005;294:2043–51. <http://dx.doi.org/10.1001/jama.294.16.2043>
- Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. *N Engl J Med*. 2009;360:244–56. <http://dx.doi.org/10.1056/NEJMoa0800836>
- Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Infect Dis*. 2010;201:32–41. <http://dx.doi.org/10.1086/648593>
- Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. *J Infect Dis*. 2007;196:1346–54. <http://dx.doi.org/10.1086/521626>
- Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent *Streptococcus pneumoniae* serotype 19A in the United States, 2005. *J Infect Dis*. 2008;197:1016–27. <http://dx.doi.org/10.1086/528996>
- Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children—Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Morb Mortal Wkly Rep*. 2010;59:258–61.
- Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. *Pediatr Infect Dis J*. 2013;32:203–7. <http://dx.doi.org/10.1097/INF.0b013e318275614b>
- Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. *Lancet Infect Dis*. 2015;15:301–9. [http://dx.doi.org/10.1016/S1473-3099\(14\)71081-3](http://dx.doi.org/10.1016/S1473-3099(14)71081-3)
- Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N Engl J Med*. 2013;369:155–63. <http://dx.doi.org/10.1056/NEJMoa1209165>
- Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. *Clin Infect Dis*. 2014;58:918–24. <http://dx.doi.org/10.1093/cid/ciu006>
- Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. *Clin Infect Dis*. 2014;59:1724–32. <http://dx.doi.org/10.1093/cid/ciu683>


15. Kaplan SL, Center KJ, Barson WJ, Ling-Lin P, Romero JR, Bradley JS, et al. Multicenter surveillance of *Streptococcus pneumoniae* isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. *Clin Infect Dis*. 2015;60:1339–45.
16. Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, et al. Decline in antibiotic resistance and changes in the serotype distribution of *Streptococcus pneumoniae* isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Network. *Clin Microbiol Infect*. 2015;21:35–42. <http://dx.doi.org/10.1016/j.cmi.2014.08.009>
17. Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. *MMWR Surveill Summ*. 2017;66:1–28. <http://dx.doi.org/10.15585/mmwr.ss6611a1>
18. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. *Vaccine*. 2013;31:6232–8. <http://dx.doi.org/10.1016/j.vaccine.2013.10.032>
19. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, et al.; Oxford Invasive Pneumococcal Surveillance Group. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. *J Infect Dis*. 2014;210:1001–11. <http://dx.doi.org/10.1093/infdis/jiu213>
20. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clin Infect Dis*. 2014;59:1066–73. <http://dx.doi.org/10.1093/cid/ciu524>
21. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. *Lancet Infect Dis*. 2015;15:535–43. [http://dx.doi.org/10.1016/S1473-3099\(15\)70044-7](http://dx.doi.org/10.1016/S1473-3099(15)70044-7)
22. Alari A, Chaussade H, Domenech De Cellès M, Le Fouler L, Varon E, Opatowski L, et al. Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis. *BMC Med*. 2016;14:211. <http://dx.doi.org/10.1186/s12916-016-0755-7>
23. Hays C, Vermee Q, Agathine A, Dupuis A, Varon E, Poyart C, et al.; the ORP Ile de France Ouest. Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children. *Eur J Clin Microbiol Infect Dis*. 2017;36:831–8. <http://dx.doi.org/10.1007/s10096-016-2868-5>
24. Gertz RE Jr, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, et al.; Active Bacterial Core Surveillance Team. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. *J Infect Dis*. 2010;201:770–5. <http://dx.doi.org/10.1086/650496>
25. Richter SS, Heilmann KP, Dohm CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. *Emerg Infect Dis*. 2013;19:1074–83. <http://dx.doi.org/10.3201/eid1907.121830>
26. Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA, Jones RN. Serotype distribution and antimicrobial susceptibility of USA *Streptococcus pneumoniae* isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. *Diagn Microbiol Infect Dis*. 2014;80:19–25. <http://dx.doi.org/10.1016/j.diagmicrobio.2014.05.020>
27. Richter SS, Musher DM. The ongoing genetic adaptation of *Streptococcus pneumoniae*. *J Clin Microbiol*. 2017;55:681–5. <http://dx.doi.org/10.1128/JCM.02283-16>
28. Olarte L, Kaplan SL, Barson WJ, Romero JR, Lin PL, Tan TQ, et al. Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States. *J Clin Microbiol*. 2017;55:724–34. <http://dx.doi.org/10.1128/JCM.01778-16>
29. van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. *BMC Infect Dis*. 2015;15:207. <http://dx.doi.org/10.1186/s12879-015-0941-9>
30. Janoir C, Lepoutre A, Gutmann L, Varon E. Insight into resistance phenotypes of emergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolated from invasive disease after 13-valent pneumococcal conjugate vaccine implementation in France. *Open Forum Infect Dis*. 2016;3:ofw020. <http://dx.doi.org/10.1093/ofid/ofw020>
31. Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Ubukata K; Invasive Pneumococcal Diseases Surveillance Study Group. Changes in capsule and drug resistance of pneumococci after introduction of PCV7, Japan, 2010–2013. *Emerg Infect Dis*. 2014;20:1132–9. <http://dx.doi.org/10.3201/eid2007.131485>
32. Ubukata K, Chiba N, Hanada S, Morozumi M, Wajima T, Shouji M, et al.; Invasive Pneumococcal Diseases Surveillance Study Group. Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013. *Emerg Infect Dis*. 2015;21:1956–65. <http://dx.doi.org/10.3201/eid2111.142029>
33. Chiba N, Morozumi M, Ubukata K. Application of the real-time PCR method for genotypic identification of  $\beta$ -lactam resistance in isolates from invasive pneumococcal diseases. *Microb Drug Resist*. 2012;18:149–56. <http://dx.doi.org/10.1089/mdr.2011.0102>
34. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 25th informational supplement (M100–S25). Wayne (PA): The Institute; 2015.
35. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *Lancet Infect Dis*. 2011;11:760–8. [http://dx.doi.org/10.1016/S1473-3099\(11\)70090-1](http://dx.doi.org/10.1016/S1473-3099(11)70090-1)
36. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. *Lancet*. 2011;378:1962–73. [http://dx.doi.org/10.1016/S0140-6736\(10\)62225-8](http://dx.doi.org/10.1016/S0140-6736(10)62225-8)
37. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al.; Microbiologists of Epibac; ORP Networks. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. *Vaccine*. 2015;33:359–66. <http://dx.doi.org/10.1016/j.vaccine.2014.11.011>
38. Gaviria-Agudelo CL, Jordan-Villegas A, Garcia C, McCracken GH Jr. The effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease. *J Pediatric Infect Dis Soc*. 2017;6:253–9. <http://dx.doi.org/10.1093/jpids/piw005>
39. Olarte L, Barson WJ, Barson RM, Romero JR, Bradley JS, Tan TQ, et al. Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era. *Clin Infect Dis*. 2017;64:1699–704. <http://dx.doi.org/10.1093/cid/cix115>
40. Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. *Vaccine*. 2015;33(Suppl 4):D60–5. <http://dx.doi.org/10.1016/j.vaccine.2015.05.102>
41. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. *PLoS One*. 2015;10:e0131494. <http://dx.doi.org/10.1371/journal.pone.0131494>
42. Weinberger R, von Kries R, van der Linden M, Rieck T, Siedler A, Falkenhorst G. Invasive pneumococcal disease in children under 16 years of age: incomplete rebound in incidence

- after the maximum effect of PCV13 in 2012/13 in Germany. *Vaccine*. 2018;36:572–7. <http://dx.doi.org/10.1016/j.vaccine.2017.11.085>
43. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al.; Adult Pneumonia Study Group-Japan. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. *Lancet Infect Dis*. 2017;17:313–21. [http://dx.doi.org/10.1016/S1473-3099\(17\)30049-X](http://dx.doi.org/10.1016/S1473-3099(17)30049-X)
  44. Beall B, McEllistrem MC, Gertz RE Jr, Boxrud DJ, Besser JM, Harrison LH, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of *Streptococcus pneumoniae* within the United States. *J Infect Dis*. 2002;186:118–22. <http://dx.doi.org/10.1086/341072>
  45. Ko KS, Baek JY, Song JH. Multidrug-resistant *Streptococcus pneumoniae* serotype 6D clones in South Korea. *J Clin Microbiol*. 2012;50:818–22. <http://dx.doi.org/10.1128/JCM.05895-11>
  46. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. *PLoS Pathog*. 2007;3:e168. <http://dx.doi.org/10.1371/journal.ppat.0030168>
  47. Wyres KL, Lambertsen LM, Croucher NJ, McGee L, von Gottberg A, Liñares J, et al. Pneumococcal capsular switching: a historical perspective. *J Infect Dis*. 2013;207:439–49. <http://dx.doi.org/10.1093/infdis/jis703>
  48. Chiba N, Murayama SY, Morozumi M, Iwata S, Ubukata K. Genome evolution to penicillin resistance in serotype 3 *Streptococcus pneumoniae* by capsular switching. *Antimicrob Agents Chemother*. 2017;61:e00478–17. <http://dx.doi.org/10.1128/AAC.00478-17>


Address for correspondence: Kimiko Ubukata, Keio University School of Medicine, Department of Infectious Diseases, 35 Shinanomachi Shinjyuku-ku, Tokyo 160-8582, Japan; email: [ubukatak@keio.jp](mailto:ubukatak@keio.jp)

## May 2017: Antimicrobial Resistance

- Exposure Characteristics of Hantavirus Pulmonary Syndrome Patients, United States, 1993–2015
- Increased Neurotropic Threat from *Burkholderia pseudomallei* Strains with a *B. mallei*-like Variation in the *bimA* Motility Gene, Australia
- Population Genomics of *Legionella longbeachae* and Hidden Complexities of Infection Source Attribution
- Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
- Lack of Durable Cross-Neutralizing Antibodies against Zika Virus from Dengue Virus Infection
- Use of Blood Donor Screening Data to Estimate Zika Virus Incidence, Puerto Rico, April–August 2016



- Invasive Nontuberculous Mycobacterial Infections among Cardiothoracic Surgical Patients Exposed to Heater–Cooler Devices
- Anthrax Cases Associated with Animal-Hair Shaving Brushes
- Increasing Macrolide and Fluoroquinolone Resistance in *Mycoplasma genitalium*
- Survey of Treponemal Infections in Free-Ranging and Captive Macaques, 1999–2012
- Estimated Incubation Period for Zika Virus Disease



- Population Responses during the Pandemic Phase of the Influenza A(H1N1)pdm09 Epidemic, Hong Kong, China
- Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012
- No Such Thing as Chronic Q Fever
- Reassortant Clade 2.3.4.4 Avian Influenza A(H5N6) Virus in a Wild Mandarin Duck, South Korea, 2016
- Amoxicillin and Ceftriaxone as Treatment Alternatives to Penicillin for Maternal Syphilis
- Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in *Neisseria gonorrhoeae*, Hawaii, USA
- Regional Transmission of *Salmonella* Paratyphi A, China, 1998–2012
- Exposure Risk for Infection and Lack of Human-to-Human Transmission of *Mycobacterium ulcerans* Disease, Australia
- Virulence Analysis of *Bacillus cereus* Isolated after Death of Preterm Neonates, Nice, France
- The Discovery of Penicillin—New Insights after More than 75 years of Clinical Use
- Persistence of Zika Virus in Breast Milk after Infection in Late Stage of Pregnancy

# Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010–2017

## Technical Appendix

**Technical Appendix Table 1.** Serotypes, penicillin-resistant and macrolide-resistant genotypes for all isolates (n = 2,849) from patients with invasive pneumococcal disease, Japan, April 2010–March 2017

Serotype (n)	Penicillin resistance genotype*	Macrolide resistance†			
		Non n = 258	<i>erm</i> (B) n = 1,704	<i>mef</i> (A) n = 557	<i>mef</i> (A) and <i>erm</i> (B) n = 330
4 (58)	gPISP ( <i>pbp2x</i> )			1	
	gPSSP	7	2	48	
6B (237)	gPRSP		117	23	10
	gPISP ( <i>pbp1a+2x</i> )	2	14	26	2
	gPISP ( <i>pbp2x+2b</i> )		6	2	
	gPISP ( <i>pbp2x</i> )		26	7	
9V (31)	gPSSP	2			
	gPRSP		1		
14 (111)	gPISP ( <i>pbp2x</i> )		5	24	
	gPSSP		1		
	gPRSP	3	31	8	
	gPISP ( <i>pbp1a+2x</i> )		54	6	1
18C (15)	gPISP ( <i>pbp2x+2b</i> )		4	1	
	gPISP ( <i>pbp2x</i> )		2		
	gPSSP	1			
	gPSSP	9	2	4	
19F (107)	gPRSP		10	80	4
	gPISP ( <i>pbp1a+2x</i> )			3	2
	gPISP ( <i>pbp1a+2b</i> )		1		
	gPISP ( <i>pbp2x+2b</i> )			1	
	gPISP ( <i>pbp2x</i> )		3	2	
23F (128)	gPSSP	1			
	gPRSP	2	41	22	57
	gPISP ( <i>pbp1a+2x</i> )		3		
	gPISP ( <i>pbp2x+2b</i> )		2		
1 (36)	gPISP ( <i>pbp2x</i> )			1	
	gPSSP	11	9	16	
3 (314)	gPRSP		1		1
	gPISP ( <i>pbp2x</i> )	15	279	2	
	gPISP ( <i>pbp2b</i> )		1		
5 (1)	gPSSP	11	3	1	
	gPSSP		1		
6A (58)	gPRSP	3	25	6	7
	gPISP ( <i>pbp1a+2x</i> )	2	3	1	
	gPISP ( <i>pbp2x</i> )	1	6	2	
7F (60)	gPSSP	2			
	gPISP ( <i>pbp2x</i> )		4		
19A (290)	gPSSP	15	28	13	
	gPRSP		1	1	89
	gPISP ( <i>pbp1a+2x</i> )	1	7	1	28
	gPISP ( <i>pbp2x+2b</i> )				3
8 (2)	gPISP ( <i>pbp2x</i> )	4	3	51	85
	gPSSP	4	7	4	1
	gPSSP	2			
10A (123)	gPISP ( <i>pbp1a+2x</i> )	8	3		1
	gPISP ( <i>pbp2x+2b</i> )		1		
	gPISP ( <i>pbp2x</i> )	9	86	4	
	gPSSP	2	9		

Serotype (n)	Penicillin resistance genotype*	Macrolide resistance†			
		Non n = 258	<i>erm(B)</i> n = 1,704	<i>mef(A)</i> n = 557	<i>mef(A)</i> and <i>erm(B)</i> n = 330
11A (67)	gPISP ( <i>pbp1a+2x</i> )			2	
	gPISP ( <i>pbp2x</i> )	10		3	26
	gPSSP	2	1	23	
12F (108)	gPISP ( <i>pbp2x+2b</i> )		2		
	gPISP ( <i>pbp2b</i> )		98		
	gPSSP	4	4		
15B (68)	gPRSP		1	1	
	gPISP ( <i>pbp1a+2x</i> )		12		
	gPISP ( <i>pbp2x</i> )		50	1	1
	gPSSP	1		1	
20 (23)	gPSSP	3	19	1	
22F (169)	gPISP ( <i>pbp1a+2x</i> )			1	
	gPISP ( <i>pbp2x</i> )	43	85	30	
	gPSSP	7	3		
33F (42)	gPISP ( <i>pbp2x</i> )			5	
	gPSSP	2	34	1	
6C (154)	gPRSP		1	1	
	gPISP ( <i>pbp1a+2x</i> )		1		
	gPISP ( <i>pbp2x+2b</i> )	16	22	18	1
	gPISP ( <i>pbp2x</i> )	4	62	25	
	gPSSP	2	1		
6D (2)	gPRSP		1	1	
7C (10)	gPSSP		10		
13 (1)	gPRSP		1		
15A (144)	gPRSP		77		
	gPISP ( <i>pbp1a+2x</i> )		56		
	gPISP ( <i>pbp1a+2b</i> )		7		
	gPISP ( <i>pbp2x</i> )		2		1
	gPSSP			1	
15C (53)	gPRSP		2		
	gPISP ( <i>pbp1a+2x</i> )		9	1	
	gPISP ( <i>pbp2x</i> )		40	1	
16F (8)	gPRSP			4	
	gPISP ( <i>pbp1a+2x</i> )			2	
	gPSSP	2			
18B (1)	gPSSP	1			
21 (2)	gPISP( <i>pbp2x</i> )	1		1	
23A (112)	gPRSP		1		
	gPISP ( <i>pbp2x+2b</i> )	1	104		
	gPISP ( <i>pbp2x</i> )		1		3
	gPSSP	2			
23B (8)	gPRSP	1			
	gPISP ( <i>pbp2x+2b</i> )	2			
	gPISP ( <i>pbp2x</i> )	1			
	gPSSP	2	1	1	
24F (100)	gPISP ( <i>pbp1a+2x</i> )		1		
	gPISP ( <i>pbp2x</i> )		2		
	gPSSP		97		
24B (17)	gPSSP		17		
28A (1)	gPSSP	1			
31 (5)	gPSSP	5			
34 (32)	gPRSP		1		
	gPISP( <i>pbp2x</i> )	3	1	9	
	gPSSP	5	13		
35B (106)	gPRSP	6	9	33	7
	gPISP ( <i>pbp1a+2x</i> )		1		
	gPISP ( <i>pbp2x</i> )		42	1	
	gPSSP		7		
37 (8)	gPSSP	5	2	1	
38 (37)	gPISP ( <i>pbp2x+2b</i> )		1		
	gPISP ( <i>pbp2x</i> )	1		22	
	gPSSP	8		5	

\* 1a, 2x, and 2b in parenthesis indicate abnormal *pbp1a*, *pbp2x*, and *pbp2b* genes, respectively.

†Each gene mediates macrolide resistance such as clarithromycin (CLR) and azithromycin (AZM).

**Technical Appendix Table 2.** MIC<sub>50</sub>, MIC<sub>90</sub>, and MIC range of 6 intravenous antimicrobial agents for isolates from patients with invasive pneumococcal disease from April 2014 to March 2017 (n = 1229)

Antimicrobial agent	Concentration (µg/mL)		
	MIC <sub>50</sub>	MIC <sub>90</sub>	MIC range
Penicillin	0.063	2	0.016–4
Ampicillin	0.063	2	0.016–8
Cefotaxime	0.25	1	0.008–8
Meropenem	0.008	0.5	0.008–1
Levofloxacin	2	2	0.5–32
Vancomycin	0.5	1	0.5–1

**Technical Appendix 3.** Serotypes, resistance genotypes, and multilocus sequence types for all isolates (n = 2,849) from patients with invasive pneumococcal disease, Japan, April 2010 - March 2017


Serotype	Resistance genotype†	Clonal complex (n)	Sequence type (n)
<b>PCV13</b>			
4	gPISP(2x)	81 (1)	899 (1)
	gPSSP	81 (51); 3784 (1); 5902 (1); none (4)	246 (43) 695 (1) 899 (5) 7880 (1) 8649 (1); 7776 (1); 13576 (1)*; 5872 (4)
6B	gPRSP	156 (84); 81 (28); none (11); 9789 (9); 2224 (8); 2924 (5); Singleton (3); 242 (2)	90 (66) 95 (3) 273 (5) 5497 (3) 7417 (1) 7827 (1) 7831 (2) 7870 (1) 13591 (1)* 13593 (1)*; 81 (1) 282 (1) 902 (19) 2923 (1) 3849 (1) 7492 (2) 8345 (1) 8644 (1) 8648(1); 5232 (10) 7967 (1); 2756 (3) 3787 (6); 2224 (7) 7835 (1); 6413 (5); 5244 (3); 242 (2)
	gPISP(1a+2x)	156 (23); 2224 (14); 7834 (4); 2924 (2); Singleton (1)	2983 (16) 5497 (5) 7824 (2); 2224 (13) 7826 (1); 7834 (4); 6183 (2); 13046 (1)
	gPISP(2x+2b)	81 (5); 156 (1); 2924 (1); 7834 (1)	902 (3) 7965(1) 12044 (1); 5830 (1); 8348 (1); 7834 (1)
	gPISP(2x)	81 (15); 156 (12); 2924 (4); 7834 (1); Singleton (1)	902 (1) 2923 (11) 5245 (1) 6430 (2); 273 (1) 2983 (7) 7839 (2) 10194 (2); 2924 (4); 7834 (1); 13048 (1)
9V	gPSSP	2224 (1); 7585 (1)	2224(1); 6771(1)
	gPRSP	156 (1)	166 (1)
	gPISP(2x)	156 (29)	280 (18) 5231 (11)
14	gPSSP	156 (1)	280 (1)
	gPRSP	343 (30); 156 (5); 15 (2); 230 (1); 63 (1); 199 (1); 320 (1); Singleton (1)	343 (23) 554 (2) 3388 (1) 7837 (1) 7971 (2) 7974 (1); 156 (2) 5493 (3); 2922 (2); 230 (1); 782 (1); 876(1); 236 (1); 8642 (1)
18C	gPISP(1a+2x)	15 (41); 230 (19); 3111 (1)	13 (3) 2922 (38); 5240 (17) 7966 (1) 7973 (1); 13571 (1)*
	gPISP(2x+2b)	343 (4); 15 (1)	343 (2); 554(2); 15 (1)
	gPISP(2x)	156 (2)	124 (1) 7972 (1)
	gPSSP	156 (1)	124 (1)
19F	gPSSP	3594 (14); 870 (1)	3594 (13) 7829 (1); 870 (1)
	gPRSP	320 (88); 156 (3); 63 (1); 81 (1); 242 (1)	236 (77) 926 (1) 1421 (1) 1428 (1) 1464(1) 4472 (1) 7873 (2) 7991 (1) 8341 (1) 8344 (1) 13044 (1); 7993 (1) 8352 (2); 10211 (1); 81 (1); 8650 (1)
23F	gPISP(1a+2x)	156 (2); 320 (1); 3111 (1); Singleton (1)	1263 (1) 7993 (1); 926 (1); 3111 (1); 12001(1)
	gPISP(1a+2b)	156 (1)	7993 (1)
	gPISP(2x+2b)	320 (1)	236 (1)
	gPISP(2x)	320 (3); 177 (1); 2924 (1)	236 (2) 257 (1); 179 (1); 6183 (1)
	gPSSP	251 (1)	654 (1)
1	gPRSP	242 (59); 2924 (55); 156 (6); 81 (1); 5832 (1)	242 (48) 1435 (3) 1444 (1) 3589 (1) 7386 (1) 7832 (1) 7968 (1) 8343 (1) 10409 (1) 13575 (1)*; 1437 (51) 6434 (1) 7836 (1) 7872 (2); 338 (5) 2777 (1); 1623 (1); 7989 (1)
	gPISP(1a+2x)	63 (2); 242 (1)	63 (1) 8643 (1); 5844 (1)
	gPISP(2x+2b)	156 (2)	338 (1) 5242 (1)
	gPISP(2x)	242 (1)	242 (1)
3	gPSSP	306 (34); 217 (2)	306 (33) 5239 (1); 5002 (2)
	gPRSP	156 (1); 242 (1)	166 (1); 242 (1)
5	gPISP(2x)	180 (292); 99 (1); 113 (1); 156 (1); 242 (1)	180 (277) 5234 (5) 7875 (1) 7877 (1) 7878 (1) 8646 (1) 8652 (1) 10025 (1) 10420 (2) 11192 (1) 11997 (1); 99 (1); 13045 (1); 1263 (1); 7386 (1)
	gPISP(2b)	1527 (1)	13574 (1)*
	gPSSP	180 (13); Singleton (2)	180 (10) 505 (1) 2570 (1) 12002 (1); 10216 (1) 12005 (1)
6A	gPSSP	289 (1)	289 (1)
	gPRSP	9789 (25); 81 (12); 156 (1); 3115 (1); Singleton (2)	2756 (17) 3113 (1) 6432 (2) 6437 (2) 7825 (2) 8350 (1); 81 (6) 282 (5) 13572 (1)*; 90 (1); 3115 (1); 5244 (1) 7871 (1)
	gPISP(1a+2x)	9789 (3); 156 (1); 2924 (1); Singleton (1)	3113 (2) 3787 (1); 5833 (1); 6183 (1); 11998 (1)

Serotype	Resistance genotype†	Clonal complex (n)	Sequence type (n)
	gPISP(2x)	9789 (7); 81 (2)	3113 (5) 3787 (1) 7969 (1); 2923 (2)
	gPSSP	9789 (1); Singleton (1)	4271 (1); 8347 (1)
7F	gPISP(2x)	191 (4)	191 (4)
	gPSSP	191 (54); 218 (2)	191 (54); 405 (2)
19A	gPRSP	3111 (86); 156 (1); 320 (4)	3111 (85) 9045 (1); 156 (1); 320 (4)
	gPISP(1a+2x)	3111 (28); 2331 (9)	3111 (27) 7988 (1); 2331 (1) 5237 (8)
	gPISP(2x+2b)	3111 (3)	3111 (3)
	gPISP(2x)	3111 (89); 2331 (54)	3111 (88) 7988 (1); 2331 (52) 13047 (2)
	gPSSP	2331 (13); 3111 (3)	2331 (9) 5842 (4); 3111 (2) 8339 (1)
NVT			
8	gPSSP	156 (1); none (1)	11999 (1); 6022 (1)
10A	gPISP(1a+2x)	156 (9); 113 (2); Singleton (1)	1263 (8) 7773 (1); 5236 (2); 3078 (1)
	gPISP(2x+2b)	156 (1)	5246 (1)
	gPISP(2x)	113 (84); 156 (15)	5236 (84); 1263 (11) 3395 (1) 7773 (1) 7830 (2)
	gPSSP	113 (9); 156 (2)	5236 (9); 1263 (1) 12051 (1)
11A	gPISP(1a+2x)	99 (2)	99 (2)
	gPISP(2x)	99 (38); 62 (1)	99 (30) 7153 (7) 7811 (1); 1760 (1)
	gPSSP	99 (23); 62 (3)	99 (21) 7153 (1) 8651 (1); 62 (2) 1012 (1)
12F	gPISP(2x+2b)	1527 (2)	4846 (2)
	gPISP(2b)	1527 (98)	4846 (98)
	gPSSP	1527 (7); 989 (1)	6945 (6) 12003 (1); 989 (1)
15B	gPRSP	81 (1); 242 (1)	83 (1); 242 (1)
	gPISP(1a+2x)	199 (12)	199 (12)
	gPISP(2x)	199 (52)	199 (51) 5609 (1)
	gPSSP	199 (2)	199 (2)
20	gPSSP	4745 (20); 99 (1); 235 (1); 5349 (1)	4745 (16) 7828 (4); 99 (1); 235 (1); 5190 (1)
22F	gPISP(1a+2x)	433 (1)	4553 (1)
	gPISP(2x)	433 (147); 113 (11)	433 (145) 819 (1) 10023 (1); 5236 (2) 7158 (9)
	gPSSP	433 (5); 113 (2); 2572 (1); 3594 (1); none (1)	433 (5); 7158 (1) 8353 (1); 5496 (1); 3594 (1); 3465 (1)
33F	gPISP(2x)	100 (5)	100 (5)
	gPSSP	717 (34); 62 (2); 100 (1)	717 (34); 673 (2); 100 (1)
6C	gPRSP	156 (1); 5832 (1)	8352 (1); 5832 (1)
	gPISP(1a+2x)	2924 (1)	12080 (1)
	gPISP(2x+2b)	156 (30); 5832 (24); 315 (2); Singleton (1)	5241 (29) 12081 (1); 5025 (2) 5832 (20) 7384 (2); 386 (2); 9025 (1)
	gPISP(2x)	2924 (59); 81 (23); 7781 (4); 156 (2); 9789 (2); 242 (1)	2924 (37) 6183 (16) 7838 (1) 7879 (1) 9336 (2) 12080 (1) 12082 (1); 2923 (23); 7788 (2) 7876 (2); 4233 (1) 13587 (1)*; 3787 (2); 242 (1)
6D	gPSSP	156 (1); 473 (1); 7781 (1)	8645 (1); 473 (1); 2789 (1)
	gPRSP	81 (1); 156 (1)	282 (1); 90 (1)
7C	gPSSP	2758 (10)	2758 (10)
13	gPRSP	156 (1)	10303 (1)
15A	gPRSP	63 (77)	63 (73) 2105 (1) 2771 (1) 8354 (1) 12000 (1)
	gPISP(1a+2x)	63 (56)	63 (42) 7874 (13) 10211 (1)
	gPISP(1a+2b)	63 (6); Singleton (1)	63 (6); 8346 (1)
	gPISP(2x)	292 (2) 113 (1)	292 (2); 7992 (1)
	gPSSP	292 (1)	292 (1)
15C	gPRSP	81 (2)	83 (1) 6138 (1)
	gPISP(1a+2x)	199 (10)	199 (9) 1674 (1)
	gPISP(2x)	199 (41)	199 (39) 9222 (1) 12073 (1)
16F	gPRSP	3117 (4)	8351 (4)
	gPISP(1a+2x)	3117 (2)	3117 (2)
	gPSSP	3117 (2)	3117 (2)
18B	gPSSP	3594 (1)	3594 (1)
21	gPISP(2x)	1381 (2)	1233 (2)
23A	gPRSP	156 (1)	9619 (1)
	gPISP(2x+2b)	156 (105)	338 (57) 2612 (1) 3437 (1) 5242 (39) 5246 (5) 6685 (1) 8340 (1)
	gPISP(2x)	156 (4)	338 (1) 10000 (3)
	gPSSP	439 (2)	42 (1) 438 (1)
23B	gPRSP	156 (1)	2372 (1)
	gPISP(2x+2b)	156 (2)	1373 (2)
	gPISP(2x)	439 (1)	439 (1)
	gPSSP	439 (3); 63 (1)	439 (3); 63 (1)
24	gPISP(1a+2x)	230 (1)	230 (1)
	gPISP(2x)	2572 (2)	2572 (2)
	gPSSP	2572 (112); 4982 (2)	2572 (62) 5496 (50); 4982 (2)

Serotype	Resistance genotype†	Clonal complex (n)	Sequence type (n)
28A	gPSSP	546 (1)	11601 (1)
31	gPSSP	7800 (5)	11184 (5)
34	gPRSP	15 (1)	9395 (1)
	gPISP(2x)	none (12); 15 (1)	3116 (12); 7388 (1)
	gPSSP	15 (13); none (5)	1439 (1) 7388 (12); 3116 (5)
35B	gPRSP	558 (53); 156 (1); Singleton (1)	558 (49) 1204 (2) 7809 (2); 156 (1); 7990 (1)
	gPISP(1a+2x)	1816 (1)	2755 (1)
	gPISP(2x)	1816 (43)	2755 (42) 12004 (1)
	gPSSP	1816 (7)	2755 (7)
37	gPSSP	447 (8)	447 (6) 7970 (2)
38	gPISP(2x+2b)	none (1)	7833 (1)
	gPISP(2x)	6429 (23)	6429 (23)
	gPSSP	393 (12); 6429 (1)	393 (12); 6429 (1)


\*STs newly identified in this study.

† 1a, 2x, and 2b in the parenthesis indicate *pbp1a*, *pbp2x* and *pbp2b* genes, respectively. PBPs (PBP1A, PBP2X, and PBP2B) involved in peptidoglycan synthesis are encoded by these genes. Amino acid substitutions within or near each PBP's conserved amino acid motifs were identified in resistance strains with various combinations of abnormal genes.




**Technical Appendix Figure 1.** Distribution of isolates collected by the surveillance for invasive pneumococcal disease in Japan from April 2010 to March 2017. Numbers of isolates obtained from children/adults are shown for each locality on the map.







**Technical Appendix Figure 2.** Yearly changes of serotypes and penicillin-resistant genotypes among isolates from children with invasive pneumococcal disease in Japan from April 2010 to March 2017. I, II, and III on horizontal axis represent three surveillance periods as follows: pre-PCV7 period, from April 2010 through March 2011; PCV7 period, from April 2011 to March 2014; and PCV13 period, from April 2014 through March 2017. gPSSP, genotypic penicillin-susceptible *Streptococcus pneumoniae*; gPISP, genotypic penicillin-intermediate resistant *S. pneumoniae*; gPRSP, genotypic penicillin-resistant *S. pneumoniae*. Parentheses enclose mutated *pbp* genes, *pbp1a*, *pbp2x*, and/or *pbp2b*, that mediate penicillin resistance.



**Technical Appendix Figure 3.** Yearly changes of serotypes and penicillin-resistant genotypes among isolates from adults with invasive pneumococcal disease in Japan from April 2010 to March 2017. I, II, and III on horizontal axis represent three surveillance periods as follows: pre-PCV7 period, before vaccination to children, from April 2010 to March 2011; PCV7 period, after PCV7 vaccination to children, from April 2011 to March 2014; and PCV13 period, with PCV7 replaced by PCV13 vaccination in children, from April 2014 to March 2017. gPSSP, genotypic penicillin-susceptible *Streptococcus pneumoniae*; gPISP, genotypic penicillin-intermediate resistant *S. pneumoniae*; gPRSP, genotypic penicillin-resistant *S. pneumoniae*. Parentheses enclose mutated *pbp* genes, *pbp1a*, *pbp2x*, and/or *pbp2b*, that mediate penicillin resistance.



**Technical Appendix Figure 4.** Distribution of susceptibilities to 4 parenteral  $\beta$ -lactam antibiotics, penicillin, ampicillin, cefotaxime, and meropenem, by genotypes of isolates from patients with invasive pneumococcal disease in Japan from April 2014 to March 2017 ( $n = 1229$ ). gPSSP indicates genotypic penicillin-susceptible *Streptococcus pneumoniae*; gPISP indicates genotypic penicillin-intermediate-resistant *S. pneumoniae*; and gPRSP indicates genotypic penicillin-resistant *S. pneumoniae*. Parentheses enclose mutated *pbp* genes *pbp1a*, *pbp2x*, and/or *pbp2b*, which mediate penicillin resistance.



**Technical Appendix Figure 5.** Details of clonal complex (CC) 81 (n = 1858) included 420 sequence types (STs) from the Multilocus Sequence Typing Web site (<https://pubmlst.org/spneumoniae/>) (download October/02/2017). Data include our own from the present study (n = 143). STs of 3 gPRSPs identified in serotypes 6D, 15B, and 15C (in red) were derived from ST81, belonging to CC81. The Pneumococcal Molecular Epidemiology Network (PMEN) clones identified in CC81 also are shown (in green).